← M. Cecilia Bahit

Papers by M. Cecilia Bahit

Page 1 · newest first

1. Prospects for adiponectin-based therapeutics in myocardial ischemia reperfusion injuryPharmacology & Therapeutics · 2026
2. Effects of sacubitril/valsartan versus enalapril on NT-proBNP and hs-troponin T in patients with heart failure due to Chagas disease: insights from the PARACHUTE-HF trialEuropean Heart Journal · 2026
3. Prevention of heart failure after acute myocardial infarctionThe Lancet · 2025
4. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trialThe Lancet · 2017
5. Incidence and Predictors of Extracranial Bleeding on Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A COMBINE-AF AnalysisCirculation · 2026
6. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and SexCirculation · 2022
7. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trialEuropean Heart Journal · 2015
8. ApoA-I Infusions and Burden of Ischemic Events After Acute Myocardial InfarctionJournal of the American College of Cardiology · 2024
9. Post-Stroke Cardiovascular Complications and Neurogenic Cardiac InjuryJournal of the American College of Cardiology · 2020
10. Addressing the Global Burden of Cardiovascular Disease in WomenJournal of the American College of Cardiology · 2024
11. Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas DiseaseJAMA · 2025
12. Minimizing Missing Data in Clinical TrialsCirculation · 2025
13. Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy with Heart Failure: Baseline Characteristics of the PARACHUTE-HF TrialEuropean Journal of Heart Failure · 2025
14. Vision impairment following glucagon-like peptide-1 receptor agonist use: is it harmful?Polskie Archiwum Medycyny Wewnętrznej · 2025
15. Impact of Apolipoprotein A-I Infusions on Cardiovascular Events Post-MI by Neutrophil-Lymphocyte Ratio and LDL-Cholesterol LevelsJACC Advances · 2025
16. Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS)American Heart Journal · 2025
17. Empagliflozin in Acute Myocardial Infarction in Patients with and Without Type 2 Diabetes: A Pre-Specified Analysis of the EMPACT-MI TrialEuropean Journal of Heart Failure · 2024
18. Ischemic stroke prevention in patients with atrial fibrillation and a recent ischemic stroke, TIA, or intracranial hemorrhage: A World Stroke Organization (WSO) scientific statementENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2024
19. Barriers and facilitators to implementation of intravenous cardiovascular treatments in ambulatory settingsESC Heart Failure · 2024
20. Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II TrialEuropean Heart Journal · 2024
21. Sacubitril/Valsartan Versus Enalapril in Chronic Chagas CardiomyopathyJACC Heart Failure · 2024
22. Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trialEuropean Journal of Heart Failure · 2024
23. Empagliflozin after Acute Myocardial InfarctionNew England Journal of Medicine · 2024
24. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial InfarctionNew England Journal of Medicine · 2024
25. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI TrialCirculation · 2024
26. Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial InfarctionJournal of the American College of Cardiology · 2024
27. Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MIJournal of the American College of Cardiology · 2024
28. Patient Adherence to Secondary Prevention Therapies After an Acute Coronary Syndrome: A Scoping ReviewClinical Therapeutics · 2023
29. World Stroke Organization Brain & hEart globAl iniTiative ProgramCerebrovascular Diseases · 2023
30. Effect of Vericiguat on Left Ventricular Structure and Function in Patients with Heart Failure with Reduced Ejection Fraction: The VICTORIA Echocardiographic SubstudyEuropean Journal of Heart Failure · 2023
31. Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior StrokeJAMA Cardiology · 2022
32. Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trialEuropean Journal of Heart Failure · 2021
33. Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areasOpen Heart · 2021
34. Effect of a Quality Improvement Intervention on Adherence to Therapies for Patients With Acute Ischemic Stroke and Transient Ischemic AttackJAMA Neurology · 2019
35. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial FibrillationNew England Journal of Medicine · 2019
36. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body WeightCirculation · 2019
37. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillationHeart · 2016
38. First-Ever Stroke and Transient Ischemic Attack Incidence and 30-Day Case-Fatality Rates in a Population-Based Study in ArgentinaStroke · 2016
39. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trialAmerican Heart Journal · 2016
40. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) TrialJournal of the American Heart Association · 2015
41. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart DiseaseCirculation · 2015
42. Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trialENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2015
43. Program for the Epidemiological Evaluation of Stroke in Tandil, Argentina (PREVISTA) Study: Rationale and DesignInternational Journal of Stroke · 2013
44. Newly diagnosed atrial fibrillation linked to wake-up stroke and TIANeurology · 2013
45. Risk of cardiovascular events associated with positive serology for Chagas: a systematic reviewInternational Journal of Epidemiology · 2012
46. Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine · 2011
47. Underutilization of Evidence-Based Medications in Acute ST Elevation Myocardial InfarctionCritical Pathways in Cardiology A Journal of Evidence-Based Medicine · 2002